This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Andrew Baxter - Innovator in Kinase Inhibition
Introduction
Andrew Baxter is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit kinase activity. His work is essential in the ongoing search for effective treatments for various diseases.
Latest Patents
Andrew Baxter holds a patent for "Oxepinopyrazole derivatives as inhibitors of PI3-kinase activity." This invention is directed to compounds of formula (I) and their salts. The compounds developed by Baxter are specifically designed to inhibit PI3-kinase activity, which plays a crucial role in cellular functions and disease progression.
Career Highlights
Baxter is associated with GlaxoSmithKline Intellectual Property Development Limited, where he has been instrumental in advancing research and development in pharmaceutical innovations. His expertise in kinase inhibitors has positioned him as a key player in the industry.
Collaborations
Andrew has collaborated with talented coworkers, including Sophie Marie Bertrand and Matthew Campbell. Their combined efforts contribute to the innovative environment at GlaxoSmithKline.
Conclusion
Andrew Baxter's work in developing kinase inhibitors showcases his commitment to advancing medical science. His contributions are vital for the future of targeted therapies in treating various health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile